Open AccessThe Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
Author(s) -
Robert A. Wise,
Kenneth R. Chapman,
Benjamin M. Scirica,
Sami Z. Daoud,
Dan Lythgoe,
Esther García-Gil
Publication year - 2021
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s285068
Subject(s) - medicine , copd , exacerbation , mace , hazard ratio , placebo , randomized controlled trial , clinical endpoint , confidence interval , myocardial infarction , percutaneous coronary intervention , alternative medicine , pathology
Chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased risk of major adverse cardiovascular events (MACE) and mortality. Here, we investigate whether the safety and efficacy of aclidinium bromide differ due to exacerbation history in patients with COPD and increased cardiovascular risk.